FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.21  |  FHIR Version n/a  User: [n/a]

24677511000001100: Maexeni 150microgram/30microgram tablets (Lupin (Europe) Ltd) (product)


Status: current, Not sufficiently defined by necessary conditions definition status. Date: 23-Jul 2014. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
80149001000001111 Maexeni 150microgram/30microgram tablets (Lupin (Europe) Ltd) (product) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module
106868901000001112 Maexeni 150microgram/30microgram tablets (Lupin Healthcare (UK) Ltd) en Synonym Active Only initial character case insensitive SNOMED CT United Kingdom drug extension module


0 descendants.

Expanded Value Set


Outbound Relationships Type Target Active Characteristic Refinability Group Values
Maexeni 150microgram/30microgram tablets (Lupin (Europe) Ltd) Has excipient Excipient not declared true Inferred relationship Existential restriction modifier
Maexeni 150microgram/30microgram tablets (Lupin (Europe) Ltd) Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
Maexeni 150microgram/30microgram tablets (Lupin (Europe) Ltd) Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction none true Inferred relationship Existential restriction modifier
Maexeni 150microgram/30microgram tablets (Lupin (Europe) Ltd) Is a Product containing precisely ethinylestradiol 30 microgram and levonorgestrel 150 microgram/1 each conventional release oral tablet true Inferred relationship Existential restriction modifier
Maexeni 150microgram/30microgram tablets (Lupin (Europe) Ltd) Has active ingredient Ethinylestradiol false Inferred relationship Existential restriction modifier
Maexeni 150microgram/30microgram tablets (Lupin (Europe) Ltd) Has active ingredient Levonorgestrel false Inferred relationship Existential restriction modifier
Maexeni 150microgram/30microgram tablets (Lupin (Europe) Ltd) Has manufactured dose form Conventional release oral tablet true Inferred relationship Existential restriction modifier
Maexeni 150microgram/30microgram tablets (Lupin (Europe) Ltd) VMP prescribing status (attribute) VMP valid as a prescribable product true Inferred relationship Existential restriction modifier
Maexeni 150microgram/30microgram tablets (Lupin (Europe) Ltd) VMP non-availability indicator Available true Inferred relationship Existential restriction modifier
Maexeni 150microgram/30microgram tablets (Lupin (Europe) Ltd) Has specific active ingredient Ethinylestradiol true Inferred relationship Existential restriction modifier
Maexeni 150microgram/30microgram tablets (Lupin (Europe) Ltd) Has specific active ingredient Levonorgestrel true Inferred relationship Existential restriction modifier
Maexeni 150microgram/30microgram tablets (Lupin (Europe) Ltd) Has dispensed dose form Tablet true Inferred relationship Existential restriction modifier
Maexeni 150microgram/30microgram tablets (Lupin (Europe) Ltd) Has excipient Lactose false Inferred relationship Existential restriction modifier
Maexeni 150microgram/30microgram tablets (Lupin (Europe) Ltd) Is a Maexeni true Inferred relationship Existential restriction modifier
Maexeni 150microgram/30microgram tablets (Lupin (Europe) Ltd) Is a Actual medicinal product true Inferred relationship Existential restriction modifier

Inbound Relationships Type Active Source Characteristic Refinability Group
Maexeni 150microgram/30microgram tablets (Lupin (Europe) Ltd) 63 tablet 3 x 21 tablets Has AMP True Maexeni 150microgram/30microgram tablets (Lupin (Europe) Ltd) Inferred relationship Existential restriction modifier

This concept is not in any reference sets

Back to Start